Home

Morepen Laboratories Ltd PE Ratio

Image

Morepen Laboratories Ltd

NSE: MOREPENLAB

PE

20.8

Last updated on: Mar 31, 2025

Key Highlights

  • The P/E Ratio of Morepen Laboratories Ltd is 20.8 as of 31 Mar 9.00 AM .
  • The P/E Ratio of Morepen Laboratories Ltd changed from 12.7 on March 2020 to 22.4 on March 2024 . This represents a CAGR of 12.02% over 5 years.
  • The Latest Trading Price of Morepen Laboratories Ltd is ₹ 47.85 as of 28 Mar 15:30 .
  • The PE Ratio of Pharmaceuticals Industry has changed from 21.0 to 40.0 in 5 years. This represents a CAGR of 13.75%.
  • The PE Ratio of Automobile industry is 20.3. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.2. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 157.6. The PE Ratio of Textiles industry is 37.1 in 2024.

Historical P/E Ratio of Morepen Laboratories Ltd

No data available

Company Fundamentals for Morepen Laboratories Ltd

Image

Morepen Laboratories Ltd

NSE: MOREPENLAB

Share Price

₹ 47.85

-0.69 (-1.42%)

stock direction

Last updated on: Mar 28, 2025

Market Price of Morepen Laboratories Ltd

1M

1Y

3Y

5Y

Monitoring Morepen Laboratories Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
28 Mar 202547.85
27 Mar 202548.54
26 Mar 202547.47
25 Mar 202549.62
24 Mar 202551.72
21 Mar 202550.21
20 Mar 202548.69
19 Mar 202549.42
18 Mar 202548.11
17 Mar 202542.8

SWOT Analysis Of Morepen Laboratories Ltd

Strength

2

che

Weakness

2

che

Opportunity

0

che

Threats

0

che

BlinkX Score for Morepen Laboratories Ltd

Asset Value vs Market Value of Morepen Laboratories Ltd

Market Value

0

Asset Value

0

* All values are in ₹ crores

Competitive Comparison of P/E Ratio

Company
leftMarket Capright
Morepen Laboratories Ltd2621
Sun Pharmaceutical Industries Ltd416393
Divis Laboratories Ltd153258
Cipla Ltd116434
Torrent Pharmaceuticals Ltd109469
Mankind Pharma Ltd99974

PE Ratio of Morepen Laboratories Ltd Explained

2621

Market cap

125

Earnings

20.8X

PE Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Historical Market Cap of Morepen Laboratories Ltd

No data available

* All values are in crore

Historical Revenue, EBITDA and Net Profit of Morepen Laboratories Ltd

Revenue

EBITDA

Net Profit

No data available

* All values are in crore

Historical Dividend Payout of Morepen Laboratories Ltd

No data available

* All values are in %

About Morepen Laboratories Ltd

  • Morepen Laboratories Limited is an India-based pharmaceutical company.
  • Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin.
  • The company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast.
  • It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L. The company has three state-of-the-art manufacturing plants in the northern state of Himachal Pradesh (HP) in India.
  • The main plant at Parwanoo is inspected and approved by United States Food and Drug Administration (USFDA) for production of Loratadine, which is the best selling anti-allergy drug globally.

Morepen Laboratories Ltd News Hub

Morepen Labs soars after stellar Q1 performance

Net revenue increased by 14% year-over-year (YoY) to Rs 458.64 crore during the period under review.

Read more

12 Aug 24

Morepen Laboratories consolidated net profit rises 147.23% in the June 2024 quarter

Net profit of Morepen Laboratories rose 147.23% to Rs 36.17 crore in the quarter ended June 2024 as

Read more

12 Aug 24

Morepen Laboratories to announce Quarterly Result

Morepen Laboratories will hold a meeting of the Board of Directors of the Company on 12 August 2024.

Read more

10 Aug 24

Morepen Laboratories successfully concludes QIP issue of Rs 200 cr

Morepen Laboratories announced the successful subscription of a Qualified Institutional Placement (Q

Read more

06 Aug 24

Product Composition by Percentage (Revenue)

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for PE of Morepen Laboratories Ltd

What is the current PE Ratio of Morepen Laboratories Ltd?

The Current PE Ratio of Morepen Laboratories Ltd is 20.8 as on 31 Mar 2025.

What is the average PE Ratio of the Pharmaceuticals industry?

The average industry PE Ratio of Pharmaceuticals is 40.0 as on 31 Mar 2025.

What was the PE Ratio of Morepen Laboratories Ltd last year?

The PE Ratio of Morepen Laboratories Ltd was 33.79 last year, now the PE ratio is 20.8, showing a year-on-year growth of -38.4%.

What does the PE Ratio of Morepen Laboratories Ltd indicate about its stock?

The PE Ratio of Morepen Laboratories Ltd is 20.8. This ratio indicates that investors are willing to pay 20.8 times the earnings per share for each share of Morepen Laboratories Ltd.

What is the PE Ratio Growth of Morepen Laboratories Ltd in comparison to its Earnings per Share (EPS) growth rate?

The PE Ratio of Morepen Laboratories Ltd grew by -38.4% whereas, the EPS ratio grew by -24.6.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions